Literature DB >> 31654275

A molecular diagnostic algorithm for JAK2 V617F investigations in suspected myeloproliferative neoplasms.

Mark Alexander Catherwood1, Roisin McAllister2, Patrick McCallion2, Julie Elizabeth McGimpsey2, Andrew Hindley2, John Feerick2, Greame Greenfield2, Paul Kennedy3, Gary Benson2, Claire Arnold2, Bridgin Merron4, Mary Frances McMullin2,5.   

Abstract

Entities:  

Year:  2019        PMID： 31654275     DOI： 10.1007/s11845-019-02100-w

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN： 0021-1265            Impact factor:   1.568


× No keyword cloud information.
  20 in total

Review 1.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

2.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

Review 3.  A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.

Authors:  Mary Frances McMullin; Claire N Harrison; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper S; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Adam J Mead
Journal:  Br J Haematol       Date:  2018-11-27       Impact factor: 6.998

4.  A CBC algorithm combined with immature platelet fraction is able to identify JAK2 V617F mutation-positive polycythaemia vera patients.

Authors:  Steve Johnson; Bartrum Baker
Journal:  Int J Lab Hematol       Date:  2019-01-02       Impact factor: 2.877

5.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

Review 6.  Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.

Authors:  Elisa Rumi; Mario Cazzola
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

Review 7.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

8.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

9.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  JAK2-tree: a simple CBC-based decision rule to guide appropriate JAK2 V617F mutation testing.

Authors:  Etienne Mahe; Kasper Mønsted Pedersen; Yunus Çolak; Stig Egil Bojesen; Tarah Lynch; Gary Sinclair; Faisal Khan; Meer-Taher Shabani-Rad
Journal:  J Clin Pathol       Date:  2018-12-04       Impact factor: 3.411
View more
  1 in total

Review 1.  Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms.

Authors:  Panhong Gou; Wenchao Zhang; Stephane Giraudier
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.